GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hansoh Pharmaceutical Group Co Ltd (OTCPK:HNSPF) » Definitions » Valuation Rank

Hansoh Pharmaceutical Group Co (Hansoh Pharmaceutical Group Co) Valuation Rank


View and export this data going back to 2021. Start your Free Trial

What is Hansoh Pharmaceutical Group Co Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.


Hansoh Pharmaceutical Group Co Valuation Rank Related Terms

Thank you for viewing the detailed overview of Hansoh Pharmaceutical Group Co's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Hansoh Pharmaceutical Group Co (Hansoh Pharmaceutical Group Co) Business Description

Traded in Other Exchanges
Address
287 Xiangke Road, Pudong New District, Shanghai, CHN, 201210
Hansoh Pharmaceutical Group Co Ltd is a research and development-driven pharmaceutical company in China. The company holds a broad, diversified drug portfolio in CNS diseases, oncology, anti-infectives, and diabetes. Further, it also focuses on metabolic diseases and anti-tumor. The majority of revenue is generated from the sale of pharmaceutical products in Mainland China.